STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZEOX
  4. [8-K] Zeo ScientifiX, Inc. Reports Material Event

ZEO ScientifiX (OTCQB: ZEOX) to host ZEO Xperience training

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

ZEO ScientifiX, Inc. announced the launch of ZEO Xperience, its inaugural three-day immersive educational experience for healthcare professionals focused on regenerative medicine and biologics. The event is scheduled for October 23–25, 2026 at Pier Sixty-Six Resort in Fort Lauderdale, Florida.

ZEO Xperience is structured around three themed days: Science & Innovation, Clinical Training & Practice Growth, and a Biohacking Experience. Programming combines evidence-based scientific education, hands-on clinical training, business development strategies, and wellness technologies, aligning with the company’s mission to advance physician education and responsible adoption of regenerative biologic therapies.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
ZEO Xperience dates October 23–25, 2026 Scheduled dates for the inaugural three-day ZEO Xperience educational event
Event duration three days Length of the immersive ZEO Xperience program for healthcare professionals
Announcement date August 4, 2026 Date ZEO ScientifiX announced the launch of ZEO Xperience
Company contact phone 1-888-963-7881 Media and information contact number provided by ZEO ScientifiX
regenerative biologics medical
"healthcare professionals seeking to expand their knowledge of regenerative biologics"
clinical-stage biopharmaceutical medical
"an SEC-reporting, clinical-stage biopharmaceutical company focused on the research"
A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.
biohacking medical
"Day Three – Biohacking Experience"
forward-looking statements regulatory
"Certain statements contained in this press release should be considered forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did ZEO ScientifiX (ZEOX) announce on August 4, 2026?
ZEO ScientifiX announced the launch of ZEO Xperience, a three-day immersive educational event for regenerative medicine. It is designed for licensed healthcare professionals and combines scientific education, clinical training, and practice development focused on regenerative biologics and advanced biologic therapies.

When and where will the ZEO Xperience event by ZEO ScientifiX (ZEOX) take place?
ZEO Xperience will be held October 23–25, 2026 at the newly reimagined Pier Sixty-Six Resort in Fort Lauderdale, Florida. The program spans three days of science, clinical training, and biohacking-focused sessions for regenerative medicine practitioners.

Who is the target audience for ZEO ScientifiX (ZEOX) ZEO Xperience?
ZEO Xperience targets licensed healthcare professionals, including physicians, nurse practitioners, physician assistants, nurses, chiropractors, dentists, and podiatrists. Attendance is intentionally limited to create an interactive environment for collaboration between attendees and faculty in regenerative medicine.

What are the main components of the ZEO Xperience program offered by ZEOX?
ZEO Xperience features three components: Day One focuses on science and innovation in regenerative biologics, Day Two covers clinical training and practice growth, and Day Three offers a biohacking experience centered on performance optimization and emerging wellness technologies.

How does ZEO ScientifiX (ZEOX) describe its core business focus?
ZEO ScientifiX describes itself as a clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. It emphasizes physician education, scientific collaboration, and innovative biologic technologies to help clinicians build sustainable regenerative medicine practices.
false 0001557376 0001557376 2026-08-04 2026-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 4, 2026

 

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-55008   47-4180540
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

3321 College Avenue, Suite 246
Davie, Florida

   33314
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 963-7881

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

 

Item 8.01 Other Events.

 

On August 4, 2026, ZEO issued a press release announcing the launch of ZEO Xperience, the Company’s inaugural three-day immersive educational experience designed exclusively for healthcare professionals seeking to expand their knowledge of regenerative biologics, strengthen clinical expertise, and learn best practices for responsibly integrating advanced biologic therapies into patient care.

 

A copy of the press release is included as Exhibit 99.1 to this Report.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated August 4, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 4, 2026 ZEO SCIENTIFIX, INC.
     
  By: /s/ Ian T. Bothwell
   

Ian T. Bothwell

Chief Executive Officer and Chief Financial Officer

 

2

 

Exhibit 99.1

 

ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive

Regenerative Medicine Experience for Healthcare Professionals

 

Hosted at Fort Lauderdale’s newly reimagined Pier Sixty-Six Resort, the inaugural event combines cutting-edge biologics education, hands-on clinical training, practice growth strategies, and latest innovations.

 

DAVIE, FLORIDA — August 4, 2026 — ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”), a biologics research and products company advancing regenerative medicine, physician education, and next-generation biologic technologies, today announced the launch of ZEO Xperience, the Company’s inaugural three-day immersive educational experience designed exclusively for healthcare professionals seeking to expand their knowledge of regenerative biologics, strengthen clinical expertise, and learn best practices for responsibly integrating advanced biologic therapies into patient care.

 

Taking place October 23–25, 2026, at the newly reimagined Pier Sixty-Six Resort in Fort Lauderdale, Florida, ZEO Xperience will bring together physicians, nurse practitioners, physician assistants, nurses, chiropractors, dentists, podiatrists, and other licensed healthcare professionals from across the country for a first-of-its-kind educational experience centered on the science, clinical application, and the business of regenerative medicine.

 

Designed to move beyond the traditional conference event model, ZEO Xperience combines evidence-based scientific education with hands-on clinical learning, business development strategies, collaborative networking, and immersive longevity experiences. Attendees will gain practical insights from industry experts while exploring emerging technologies, innovative treatment approaches, and real-world strategies that can immediately be applied within their practices.

 

“Education has always been at the core of ZEO ScientifiX’s mission,” said Ian Bothwell, Chief Executive Officer of ZEO ScientifiX. “As regenerative medicine continues to evolve, healthcare professionals deserve educational experiences that go beyond lectures. ZEO Xperience was created to bring together science, innovation, and practical implementation in an environment where attendees leave with the knowledge, confidence, and relationships needed to elevate patient care and responsibly advance regenerative medicine.”

 

Sean Vega-Stanton, M.S., General Manager of ZEO ScientifiX, added:

 

“From the moment we began planning ZEO Xperience, our vision was to provide an event experience we felt was missing in this industry. We wanted to move beyond the traditional conference model and build an immersive experience where healthcare professionals don’t just listen....they engage, collaborate, learn, and leave with practical strategies they can immediately apply in their practices. Every detail, from the educational programming to the venue selection and attendee participation, was intentionally designed to deliver an exceptional experience. We hope this becomes the event that healthcare professionals look forward to attending year after year.”

 

The inaugural ZEO Xperience will feature three immersive educational experiences:

 

 

 

 

Day One – Science & Innovation

 

Attendees will explore the latest advancements in regenerative biologics through evidence-based presentations, physician-led discussions, clinical case studies, emerging research, and expert panels focused on the future of regenerative medicine.

 

Day Two – Clinical Training & Practice Growth

 

Healthcare professionals will participate in advanced clinical education, live demonstrations, procedural training, practice development sessions, patient acquisition strategies, regulatory discussions, and operational best practices designed to support successful implementation of regenerative medicine within clinical practice.

 

Day Three – Biohacking Experience

 

The conference concludes with an immersive exploration of performance optimization and innovation, featuring interactive wellness technologies, recovery modalities, metabolic optimization, and emerging tools that are helping shape the future of preventative and regenerative healthcare.

 

The launch of ZEO Xperience represents another milestone in ZEO ScientifiX’s commitment to advancing physician education, scientific collaboration, and the responsible adoption of regenerative biologic technologies. As interest in regenerative medicine continues to grow, the Company believes comprehensive, evidence-driven education remains one of the most important drivers of improved patient outcomes, clinical excellence, and long-term practice success.

 

Attendance for the inaugural event is intentionally limited to create a highly interactive educational environment and maximize opportunities for collaboration between attendees and faculty.

 

Registration is now open. For additional information and to reserve your seat, visit www.zeoscientifix.com/xperience.

 

About ZEO ScientifiX (OTCQB: ZEOX)

 

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating from Nova Southeastern University’s Center for Collaborative Research, the Company translates emerging science into scalable clinical solutions through physician education, scientific collaboration, and innovative biologic technologies. ZEO ScientifiX supports clinicians seeking to advance patient care while building sustainable regenerative medicine practices. For more information, visit www.zeoscientifix.com.

 

2

 

 

Forward-Looking Statements

 

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary materially. ZEO ScientifiX undertakes no obligation to update forward-looking statements except as required by applicable law.

 

Media Contact

 

Zeo ScientifiX, Inc.

Ashley Simioneshci

1-888-963-7881

IR@zeoscientifix.com

 

3

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents